Skip to main content

Table 2 A comparison of our results and those reported in the literature

From: Primary ectopic axillary breast cancer: a case series 

Authors

Number of cases

Age

Histology

Treatment

Follow-up

Mornard et al. [24]

2

36–62

   

Razeman et al. [25]

28

  

4: R Mastect

13: WE+LND

10 recurrences (2 years)

Erdman et al. [26]

3

    

Khan et al. [27]

3

  

1: R Mastect

2: M Mastect

1: Recurrence-free (9 years)

2: Lost from view

Badejo et al. [28]

2

  

2: R Mastect

2: Recurrence free (2 and 4 years)

Marino et al. [29]

2

  

2: WE + RT

2: Recurrence free (3 years)

Kawahara et al. [30]

59

31–84

37 IDC + 3 MC + 1 ApC + 2 Muci C + 1 MC IS

26: WE+LND

26: R Mastect

2: WE

5: Nod. Recurrence

54: Recurrence free (1 month to 13 years)

Haddad et al. [31]

2

 

1 ILC+ 1 U ADK

1: neoadj CT+ WE+LND + RT

1: WE+LND + CT + RT + HT

2 :Recurrence free (1 year)

Yanagi et al. [17]

94

26–88

52 IDC+ 5MC+ 2ILC+ 5Muci C+ 4 Ap C

6: neoadj CT + WE + LND or Mastect

84: Surgery (49 WE+ 1 WE+LND+ 3 R Mastect + 18 M Mastect + others)

72: adj treatment (RT +/− CT +/− HT)

9: Recurrences (3 nodal + 2 local + 2 bone + 1 systemic + 1 peritoneal cavity)

Our series

5

33–60

3 IDC + 1 ILC

1 MC

1: CT + RT

4: WE+LND + CT + RT

+/−HT

1: Metastasis (2 years)

4: Recurrence free

  1. ILC invasive lobular carcinoma, IDC invasive ductal carcinoma, MC medullary carcinoma, MuciC mucinous carcinoma, Ap C apocrine carcinoma, MC IS medullary carcinoma in situ, R Mastect radical mastectomy, WE+LND wide excision + lymph node dissection, M Mastect modified mastectomy, neoadj neoadjuvant, adj adjuvant, RT radiation therapy, CT chemotherapy, HT hormone therapy